<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197846</url>
  </required_header>
  <id_info>
    <org_study_id>D1443L00079</org_study_id>
    <nct_id>NCT01197846</nct_id>
  </id_info>
  <brief_title>Efficacy of Quetiapine XR Versus Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder</brief_title>
  <official_title>Efficacy of Quetiapine XR vs. Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro de Investigación Biomédica en Red de Salud Mental</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro de Investigación Biomédica en Red de Salud Mental</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot multicentric, prospective, placebo controlled, randomized double blinded, study of 12
      weeks follow-up Adult patients diagnosed of bipolar disorder I or II, in previous treatment
      with no more than two concomitant mood stabilizers at stable doses and current subsyndromal
      symptoms, defined as YMRS ≤14 and/ or MADRS≥8 and ≤14 would be included Sub-acute phases
      would be excluded (at least 8 weeks from last exacerbation would be required for inclusion).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Remission of acute episodes usually doesn't correlate with symptomatic or functional recovery
      in occupational and social domains after (McQueen et al, 2001; Tohen et al, 2000) Ongoing
      depressive symptoms are the strongest predictor of functional deficits in persons with
      bipolar disorder (Bauer et al, 2001; Judd et al, 2005). Depressive subsyndromal symptoms are
      associated to functional impairment in bipolar disorder (Vojta et al, 2001; Altshuler et al,
      2002; Yatham et al, 2004) The addition of olanzapine to valproate or lithium provided
      superior efficacy to valproate or lithium plus placebo in non completely remitted manic and
      mixed bipolar episodes, mainly through a control of depressive symptoms (Tohen et al, 2002)
      Quetiapine has demonstrated to be efficacious in the control of depressive symptoms in
      Bipolar Disorder (BOLDER, EMBOLDEN studies) and in the prevention of recurrences, maintaining
      the patient in YMRS and MADRS scores under the cut-off point between asymptomatic and
      subsyndromal states (Studies 126, 127 and 144) Thus it's expectable that adding quetiapine to
      previous mood stabilizers in bipolar patients with subsyndromal symptoms probably would
      improve their symptoms, mainly depressive, to levels not only of syndromic but of symptomatic
      remission, driving to a better functional status Quetiapine extended release would be used
      because its advantages on quetiapine immediate release regarding an easier and comfortable
      posology and potential better adherence
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of quetiapine extended release (QTP XR) vs. placebo in the control of bipolar subsyndromal symptoms when added to previous mood stabilizer treatment (lithium/ valproate/lamotrigine)</measure>
    <time_frame>Study of 12 weeks follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of QTP XR vs. placebo when added to previous mood stabilizer treatment (lithium/ valproate/lamotrigine) in functional level of bipolar patients with subsyndromal symptoms</measure>
    <time_frame>Study of 12 weeks follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine 300 mg or 600 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>quetiapine 300 mg or 600 mg</description>
    <arm_group_label>Quetiapine</arm_group_label>
    <other_name>Quetiapine XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed Consent signature

          2. At least 18 years old

          3. Diagnoses of bipolar disorder I or II (as DSM-IV-TR 4ª Ed codes)

          4. Previous treatment with a mood stabilizer (lithium, valproate or lamotrigine) at
             stable and optimum doses for at least six weeks prior to the start of the trial (i.e.,
             on the same dose and serum levels within the therapeutic ranges: 0.6-1.2 mEq/l of
             lithium or 50-100 ug/ml of valproate)

          5. Presenting subsyndromal symptoms at enrolment and randomization point, defined as YMRS
             ≤ 14 and/ or MADRS ≥ 8 and ≤14

          6. At least one manic, mixed, or depressed episode in the last 5 years

          7. Being able to understand and meet the study requirements

        Exclusion Criteria:

          1. Pregnant or nursing women

          2. Mental retardation.

          3. Current active diagnoses of any axis I or II DSM-IV-TR diagnoses different from
             bipolar disorder I or II. This doesn't apply to nicotine nor caffeine
             abuse-dependence. Punctual alcohol and/or substances use not constitutive of a
             diagnoses of abuse or dependence following DSM-IV-TR criteria wouldn't suppose the
             exclusion of the patient from the study. Anxiety in levels not constitutive of any
             anxiety disorder within those codified in DSM-IV-TR wouldn't either suppose the
             exclusion of the patient from the study

          4. Having suffered any acute episode (depressive, manic, or mixed) within the 8 weeks
             prior to enrolment, as defined in DSM-IV-TR

          5. Patients that, in the investigator's opinion, are at a high risk of suicide or mean a
             risk of aggression to others.

          6. Having been treated with any antidepressant at randomization.

          7. Having been treated with any mood stabilizer other than lithium/valproate/lamotrigine
             at randomization.

          8. Having been treated with any oral antipsychotic drug at randomization. Administration
             of a depot antipsychotic medication within one dosing interval prior to randomization
             (e.g. Long acting Risperidone 2 weeks; Zuclopenthixol 4 weeks; Pipotiazine 4 weeks;
             Flufenazine 6 weeks)

          9. Having been treated with any of the following P450-3A4 cytochrome inhibitors in the 14
             days prior to inclusion, including: ketoconazole, itraconazole, fluconazole,
             erythromycin, clarithromycin, fluvoxamine, indinavir, nelfinavir, ritonavir and
             saquinavir.

         10. Having been treated with any of the following P450-3A4 cytochrome inducers in the 14
             days prior to inclusion, including: phenytoin, carbamazepine, barbiturates,
             rifampicin, St. John's wart, and glucocorticoids.

         11. Any contraindication to the use of quetiapine fumarate in the investigator's opinion
             (including lack of response to it in previous treatment attempts)

         12. Suffering any medical condition that can effect the absorption, distribution,
             metabolism or excretion of the study treatment(s).

         13. Suffering any medical condition in decompensation or not receiving inappropriate
             treatment for it in the investigator's opinion (e.g., hyperthyroidism, angina
             pectoris, hypertension...)

         14. Suffering unstable diabetes at enrolment or randomization

         15. Absolute neutrophil count ≤ 1.5 x 109 per litre at randomization

         16. Non-compliance with the study plan.

         17. Participation in another clinical trial in the four weeks prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduard Vieta, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic I Provincial. Barcelona. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Gonzalez Pinto</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santiago Apostol. Vitoria. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benedikt Amann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Benito Menni. Barcelona. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Celso Arango</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañon. Madrid. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Manuel Crespo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge. Barcelona. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julio Bobes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Salud Mental II. Oviedo. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josefina Perez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santa Creu I Sant Pau. Barcelona. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriel Selva</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico de Valencia/ CSM Foios. Valencia. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Belen Arranz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parc Sanitari Sant Joan de Deu. Barcelona. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeronimo Saiz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal. Madrid. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptial Benito Menni</name>
      <address>
        <city>Barcelona</city>
        <zip>08830</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parc Sanitari Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <zip>08940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Menta II</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosptial Clinico Valencia/ CSM Foios</name>
      <address>
        <city>Valencia</city>
        <zip>46134</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santiago Apostol</name>
      <address>
        <city>Vitoria</city>
        <zip>01004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <last_update_submitted>September 18, 2012</last_update_submitted>
  <last_update_submitted_qc>September 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro de Investigación Biomédica en Red de Salud Mental</investigator_affiliation>
    <investigator_full_name>Celso Arango Lopez</investigator_full_name>
    <investigator_title>MD; PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

